you're not currently on a stable, clinician-managed testosterone protocol, since this specific dosing framework assumes an established TRT baseline
Anti-obesity medication (AOM) prescribing increased in June 2024 compared to March 2024 (+27.1%)
Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence
Bone resorption on the other hand, can be monitored through assessment of serum carboxy-terminal telopeptide of type I collagen (CTX-I) levels
Dark under-eye circles can be caused by various factors, including genetics, thinning skin due to aging, lack of sleep, dehydration, allergies, pigmentation irregularities, and lifestyle habits like smoking or excessive alcohol consumption
PMID:7658432 [9] Nelson ME, Bryant SM, Aks SE
